Qiagen seals another companion Dx deal with Eli Lilly; Blood test may predict life span for patients with heart problems;

> Qiagen ($QGEN) will develop yet another companion diagnostic for an Eli Lilly ($LLY) cancer drug under development, its third collaboration with the company. Story

> Researchers in Utah and Massachusetts have determined that a common complete blood count lab diagnostic test can be used to predict which patients are at risk of developing heart problems and how long they might live. Item

> Serametrix launched a new blood test meant to measure a cancer patient's level of circulating myeloid derived suppressor cells, which are known to dampen anti-tumor immunity. Item

> Researchers at Washington University in St. Louis are testing the use of sonic blasts to measure and diagnose circulation. Story

> Investigators at the University of Pennsylvania and Baylor College of Medicine are making progress with a blood test that appears to accurately diagnose concussions. Item

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.